TY - JOUR
T1 - A new avenue for treating neuronal diseases
T2 - Ceftriaxone, an old antibiotic demonstrating behavioral neuronal effects
AU - Tai, Chun-Hwei
AU - Bellesi, Michele
AU - Chen, An-Chih
AU - Lin, Chih-Li
AU - Li, Hsin-Hua
AU - Lin, Pin-Jiun
AU - Liao, Wen-Chieh
AU - Hung, Ching-Sui
AU - Schwarting, Rainer K
AU - Ho, Ying-Jui
PY - 2019/5/17
Y1 - 2019/5/17
N2 - Several neurodegenerative disorders, namely Parkinson's disease dementia, dementia with Lewy bodies, and Alzheimer's disease, share common pathophysiological features, such as (1) cognitive deficits, (2) glutamatergic hyperactivity-related excitotoxicity, and (3) deposition of α-synuclein (α-syn) and β-amyloid (Aβ). Ceftriaxone (CEF) is a well-tested and safe drug that has been used as an antibiotic for several decades. Recent studies have demonstrated the following effects of CEF: (1) increasing glutamate transporter-1 expression and glutamate reuptake and suppressing excitotoxicity, (2) binding well with α-syn and inhibition of α-syn polymerization, (3) modulating expression of genes related to Aβ metabolism, and (4) enhancing neurogenesis and recovery of neuronal density. In addition, our data revealed that CEF ameliorates seizure and abnormal neuronal firing in the brain. These results suggest the potential of CEF in treating neuronal disorders. This paper addresses the effects and pharmacology of CEF.
AB - Several neurodegenerative disorders, namely Parkinson's disease dementia, dementia with Lewy bodies, and Alzheimer's disease, share common pathophysiological features, such as (1) cognitive deficits, (2) glutamatergic hyperactivity-related excitotoxicity, and (3) deposition of α-synuclein (α-syn) and β-amyloid (Aβ). Ceftriaxone (CEF) is a well-tested and safe drug that has been used as an antibiotic for several decades. Recent studies have demonstrated the following effects of CEF: (1) increasing glutamate transporter-1 expression and glutamate reuptake and suppressing excitotoxicity, (2) binding well with α-syn and inhibition of α-syn polymerization, (3) modulating expression of genes related to Aβ metabolism, and (4) enhancing neurogenesis and recovery of neuronal density. In addition, our data revealed that CEF ameliorates seizure and abnormal neuronal firing in the brain. These results suggest the potential of CEF in treating neuronal disorders. This paper addresses the effects and pharmacology of CEF.
KW - Neurodegenerative Disorders
KW - Parkinson's disease dementia
KW - dementia with lewy bodies
KW - Alzheimer's disease
KW - cetriaxone
U2 - 10.1016/j.bbr.2019.02.020
DO - 10.1016/j.bbr.2019.02.020
M3 - Review article (Academic Journal)
C2 - 30768995
SN - 0166-4328
VL - 364
SP - 149
EP - 156
JO - Behavioural Brain Research
JF - Behavioural Brain Research
ER -